NeuroPace (NASDAQ:NPCE) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Key Points

• NeuroPace reported quarterly earnings of ($0.26) per share, missing analysts' expectations by ($0.02), and has a significant negative return on equity of 190.84%.
• The stock has a current market cap of $299.46 million and experienced a trading increase of $0.24, reaching a price of $9.13.
• Analysts have rated the stock as a "Buy" with a consensus price target of $17.00, following multiple upgrades from firms such as JPMorgan Chase & Co. and Cantor Fitzgerald.

NeuroPace (NASDAQ:NPCE - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02), Zacks reports. The business had revenue of $23.52 million during the quarter, compared to the consensus estimate of $23.08 million. NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%. NeuroPace updated its FY 2025 guidance to EPS.

NeuroPace Trading Down 5.2%

Shares of NeuroPace stock traded down $0.47 during mid-day trading on Friday, hitting $8.56. The stock had a trading volume of 285,472 shares, compared to its average volume of 198,206. The company has a quick ratio of 5.70, a current ratio of 5.47 and a debt-to-equity ratio of 3.02. The firm has a market cap of $283.16 million, a P/E ratio of -10.19 and a beta of 1.89. The firm has a 50-day moving average of $9.91 and a two-hundred day moving average of $11.72. NeuroPace has a 12-month low of $5.45 and a 12-month high of $18.98.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on NPCE shares. JPMorgan Chase & Co. lifted their price target on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a report on Wednesday, May 14th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $17.00 price target on shares of NeuroPace in a report on Wednesday, May 14th. Wells Fargo & Company lowered their price objective on shares of NeuroPace from $17.00 to $15.00 and set an "overweight" rating for the company in a research note on Wednesday. Finally, HC Wainwright started coverage on shares of NeuroPace in a research note on Wednesday, May 28th. They set a "buy" rating and a $18.00 price objective for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NeuroPace has a consensus rating of "Buy" and a consensus target price of $16.60.

Hedge Funds Weigh In On NeuroPace

A number of hedge funds have recently made changes to their positions in NPCE. Geode Capital Management LLC boosted its position in shares of NeuroPace by 44.6% during the 2nd quarter. Geode Capital Management LLC now owns 485,162 shares of the company's stock worth $5,406,000 after purchasing an additional 149,595 shares during the period. Legal & General Group Plc lifted its holdings in NeuroPace by 86.0% during the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock worth $30,000 after buying an additional 1,239 shares in the last quarter. Rhumbline Advisers lifted its holdings in NeuroPace by 114.5% during the 2nd quarter. Rhumbline Advisers now owns 36,956 shares of the company's stock worth $412,000 after buying an additional 19,729 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in NeuroPace by 59.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 71,463 shares of the company's stock worth $796,000 after buying an additional 26,547 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in NeuroPace during the 2nd quarter worth approximately $35,000. Hedge funds and other institutional investors own 78.83% of the company's stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.